zyme"), with glucose-l-phosphate as the principal product. This is converted to glucose-6-phosphate in a reversible reaction catalyzed by phosphoglucomutase. Glucose is liberated from this intermediate by glucose-6-phosphatase. Small amounts of glucose are also formed directly from glycogen through the action of amylo-1,6-glucosidase at branch points in the glycogen molecule. Other metabolic pathways open to glucose-6-phosphate are partial oxidative degradation through the "hexose monophosphate shunt" and breakdown to pyruvate and lactate via the glycolytic pathway.
Intensive biochemical studies by several investigators have led to the subclassification of hepatic glycogen disease into several types, based on determination of the activity of certain hepatic enzymes. The clinical syndrome described above has been seen in association with deficiencies of glucose-6-phosphatase, amylo-1,6-glucosidase, or phosphorylase (9, 10) . More recently, Hers reported a case which did not have a deficiency of any of these enzymes (11) . Thus the problems of the fundamental pathophysiology and the subclassification of this syndrome are not yet completely resolved. However, all cases share a basic functional abnormality-defective breakdown of liver glycogen to glucose.
The clinical test most commonly employed in the diagnosis of hepatic glycogen disease consists of observation of the blood glucose response to injection of epinephrine or glucagon. Normal children or adults respond to these agents with a prompt elevation of the blood glucose level. Patients with liver glycogen disease, on the other hand, show no response or only small and delayed increases in blood glucose concentration (1, 2, 5, 
12-14)
. This has been considered as evidence that these hormones are ineffective or, at best, only partially effective in inducing hepatic glycogenolysis in this disease.
In the course of studies of glycogen deposition diseases, we have encountered six cases of liver glycogen disease with similar metabolic abnormalities and responses to glucagon. Observations in one of these cases (J.B.) were reported previously (15) . The studies described below suggest that hepatic glycogenolysis occurred spontaneously in these patients in response to hypoglycemia and that injections of glucagon induced rapid breakdown of liver glycogen. However, the principal end-product of hepatic glycogenolysis appeared to be lactate rather than glucose.
METHODS AND CLINICAL MATERIAL
Glucose was determined by the Nelson method (16) . Lactate was determined by the Barker-Summerson method (17) and by an enzymatic method using lactic dehydrogenase (18) . Both procedures gave similar results, but since the latter is more specific and proved to be convenient and dependable, it was used for most of the determinations. Glycogen was determined by the method of Good, Kramer and Somogyi (19) , using the Nelson technique for the determination of glucose after hydrolysis.
None of the cases under study showed evidence of heart disease, skeletal myopathy or cirrhosis of the liver. Their principal diagnostic features are presented in Table  I . Additional details will be reported elsewhere (20 Patient 6. M.M. was a 1 year old white female infant admitted with the diagnosis of liver glycogen disease. At 2 days of age she had been found to have hepatomegaly and a blood glucose level of 2 mg per 100 ml. Liver biopsy at 5 days of age revealed a histologic appearance typical of liver glycogen disease (no chemical determination of glycogen content). She was a small, weak infant, with a greatly enlarged liver, who developed severe hypoglycemia after 4 hours of fasting. Bone age was 6 months. There was virtually no rise in blood glucose concentration after glucagon injection. She had hyperlipemia. Repeat liver biopsy revealed a glycogen concentration of 7.1 per cent.
RESULTS
In vitro incubation studies. After the completion of preliminary clinical studies, laparotomy was performed in Patient 1. This patient, who tolerated fasting very poorly, received a slow infusion of glucose during the night before surgery. At laparotomy a piece of liver and a small sample of rectus muscle were obtained for in vitro study. The specimens were chilled rapidly and transported to the laboratory under refrigeration. Tissue slices were cut as rapidly as possible and added to flasks containing Krebs-Ringer phosphate buffer, pH 7.4, chilled to 20 C. The order of slices entering the duplicate incubation flasks was such that no systematic effect attributable to the time of slicing would occur; i.e., the pattern used was ab . . . ba rather than aabb . . . . A liver sample was withdrawn midway through the slicing procedure for determination of the initial glycogen concentration. Refrigeration of the incubation flasks was continued until slicing was completed. All flasks were then placed in a Dubnoff shaker-incubator and incubated for 2 hours at 370 C under a continuous flow of oxygen.
Liver slices were incubated in buffer alone and with several additives. At the end of 2 hours, an aliquot was withdrawn from each flask for glucose determination, 30 per cent potassium hydroxide was added to the incubation flasks, and glycogen The results shown are after correction for incubated rat liver blanks, which were: glycogen 0, 0; glucose 4.9, 4.7 mg per g.
determination was performed. Muscle slices were incubated in Krebs-Ringer phosphate buffer without additives. Table II presents the results of liver slice incubations without additives, with glucagon, and with a homiogenate of liver obtained from a fasted normal rat. The initial liver glycogen concentration was 86 mg per g. Slices incubated without additives showed only a slight decline in glycogen content during incubation and no glucose productioll. Unequivocal stimulation of glycogenolysis was induced by glucagon. However, only small amounts of glucose appeared in the incubation medium. Incubation with rat liver homogenate, on the other hand, resulted in the production of glucose in amounts corresponding to the loss of glycogen.
In contrast to the defective glycogenolysis observed during incubation of liver slices, normal glycogen breakdown was observed during incubation of muscle. The initial muscle glycogen concentration was 1.9 mg per g, a relatively low value. After incubation it was 0.3 mg per g.
The failure to account for the products of glycogenolysis during incubation of liver slices was not anticipated and did not become known in time to permit analyses for other possible metabolites of glycogen. However, material from another incubation experiment, performed at the same time, was available. Liver slices had been incubated with C14-glucose, without hormonal additives. The flask contents had been frozen and stored for later study. This material was thawed and analyzed for glycogen, glucose and lactate. Figures 2 and 3 show blood glucose and lactate curves in association with glucose infusion or feeding. Figure 2 demonstrates reduction of lactate to normal levels after 3 hours of glucose infusion. The drop in lactate shown in Figure 3 was more rapid than that observed in most of these children after feedings; lactate rebound after 1 to 2 hours of hypoglycemia is well demonstrated.
The possibility was considered that endogenous epinephrine release secondary to hypoglycemia, and resultant glycogenolysis in muscle, might account for a major portion of the elevation in fasting lactate. In order to assess the contribution of this mechanism, epinephrine was administered to two patients at a time when their blood lactate levels were relatively low. It was reasoned that if endogenous epinephrine release played a dominant role in the production of the fasting hyper- The effect of glucagon was also examined at various intervals after feeding or glucose infusion in five of the patients. Sharp rises in the blood lactate level were obtained under all circumstances. The effect of glucagon was more dramatic if it was injected at a time when the blood lactate level was relatively "low." For example, Patient 6 had a rise in lactate of only 20 mg per 100 ml when the initial level was 122 mg per 100 ml ( Figure 4 , Table V) . On another occasion, glucagon wvas given when the blood lactate level wvas 57 mg per 100 ml, after feeding. The lactate rose to 113 mg per 100 ml in 30 minutes. On a third occasion, when the initial lactate concentration was 19 mg per 100 ml, an increase to 119 mg per 100 ml was observed 1 hour after glucagon injection. Similar results were obtained in the other children.
Since doses of epinephrine presumably sufficient to induce glycogenolysis in muscle failed to reproduce the observed elevations in lactate (Table  IV) , and since glucagon exerts little or no effect on muscle, it appeared likely that the liver was the source of the excess circulating lactate. We attempted to confirm this by an experiment based on the report of Mason and Andersen (21), who found that arterial lactate was higher than venous lactate in a child with glycogen disease. In normal individuals, in whom muscle is a principal source of circulating lactate, the concentration of this metabolite is higher in venous than in arterial blood. Venous (medial cubital vein) and capillary blood samples were obtained in Patient 3 before and after glucagon administration. The lactate concentration rose sharply after glucagon injection, as in Figure 4 . However, we did not observe a significant capillary-venous lactate difference either prior to or 30 minutes after glucagon injection. This indicates that muscle was not contributing lactate to the circulation, but does not constitute as striking evidence for the hepatic origin of the lactate as does the observation of Mason and Andersen.
The acute effect on liver size of relatively large doses of glucagon was studied in Patients 1, 2, 3, 5, and 6. These children received 1 to 2 mg of glucagon per hour for 4 hours, by intravenous infusion. A decrease in liver size was observed in all. This became apparent after the first hour and was maximal after 2 to 3 hours, at which time liver margins were 2 to 4 cm above the initial levels in Patients 1, 2 and 3, and 1 to 2 cm above 0 I HOURS CTION ON THE BLOOD GLUCOSE AND LAC-)LS. The numbers to the right of indiin Patients 5 and 6. Moderate to severe side effects were seen at this dose range, however. All five children developed restlessness and tachypnea and one vomited during the infusion. The clinical impression of acidosis was confirmed by determination of pH and bicarbonate content of blood in one patient. Distinct but relatively small changes in liver size were sometimes also observed after single subcutaneous injections of 1.0 to 1.5 mg of glucagon. These doses produced few or no side effects.
DISCUSSION
The patients discussed herein were heterogeneous with respect to hepatic enzyme assay. They include two "classic" cases of glucose-6-phosphate deficiency, one case without a demonstrated enzymatic defect, perhaps similar to that reported by Hers (11) , and one case with a previously undescribed enzymatic pattern-a deficiency in both phosphorylase and glucose-6-phosphatase. A detailed discussion of the significance of these enzyme patterns and of the subclassification of "von Gierke's disease" is beyond the scope of this paper. It must be emphasized, however, that these children form a homogeneous group in other respects.
They had greatly enlarged livers containing excess glycogen; fasting hypoglycemia, acidosis, and ketosis; hyperlipemia, and delayed growth.
Neither glucagon nor epinephrine evoked a hyperglycemic response. Spontaneous it vitro breakdown of glycogen to glucose was defective in the patients in whom this was studied. They had similar metabolic abnormalities and similar responses to glucagon. Thus, it seems appropriate to consider them together despite the differences in hepatic enzyme patterns.
Unequivocal stimulation of glycogenolysis by glucagon was demonstrated during in vitro incubation of liver slices in Patient 1. The principal end-product of this glycogenolysis was not glucose; indirect evidence suggests that it was lactate. In all six patients of this group, glucagon administration was followed by marked rises in blood lactate concentration. These increases in lactate resembled the increases in blood glucose concentration following the administration of glucagon to normal children. Comparison of capillary and venous lactate levels in one case indicated that the increment in lactate did not come from muscle. In all five children given glucagon infusions, an acute decrease in liver size was observed. Taken together, these findings suggest strongly that glucagon exerted its usual glycogeniolytic effect on the liver in these cases, but that the principal endproduct of glycogen breakdown was lactate rather than glucose. The failure to demonstrate a glucagon response in vitro in Patient 6 is disturbing and, so far, unexplained. However, this child's clinical behavior and in vivo response to glucagon was similar to that of Patient 1, where an effect on liver slices was demonstrated. Normally, the blood lactate level is low in the fasting state and rises after a carbohydrate load (22) . The fasting venous lactate concentration is higher than the arterial concentration, as muscle is a principal source of this metabolite, while the liver withdraws it from the circulation. In our patients, however, the blood lactate level was highest during fasting and decreased after feeding or glucose infusion. Muscle was not a major source of lactate. This "paradoxical" behavior is readily explained by the hypothesis that hepatic glycogenolysis was the principal source of circulating lactate in these cases. In the fasting state, hypoglycemia developed, hepatic glycogenolysis was stimulated, and the blood lactate level rose. After feeding or glucose infusion, hepatic glycogenolysis ceased, glycogen deposition supervened, and the blood lactate level fell. Glucagon produced sharp increases in blood lactate concentration under all circumstances by inducing rapid hepatic glycogenolysis. (21) presented evidence that the liver, rather than muscle, was the source of the excess lactate during fasting. Excessive production of lactic acid may be largely responsible for the fasting acidosis in some cases of this disease (21, 26) .
Confirmation of the points made above has recently appeared in an abstract by Howell, Ashton and Wyngaarden (27) . These authors studied three siblings with liver glycogen disease, one of whom was subjected to liver biopsy and found to have a deficiency of hepatic glucose-6-phosphatase. All slices incubated with glucagon showed appreciable glycogen breakdown and lactate production. The lactate concentration was higher in peripheral arterial than in venous blood, indicating that muscle was withdrawing, rather than contributing lactate to the circulation.
The phenomena discussed above are not seen in all cases of liver glycogen disease, however. Lindsay, Ross and Wigglesworth (28) reported a child whose fasting blood lactate level was only 25 mg per 100 ml. In two cases, van Creveld (23) performed blood lactate determinations; his report does not give the actual values but it may be assumed from the context that they were not remarkable. In one proven case of liver glycogen disease with glucose-6-phosphatase deficiency, recently brought under study, we have found a normal fasting blood lactate level, which did not rise after glucagon administration. No decrease in liver size was observed when this child was given a glucagon infusion. Thus, the findings described in this paper apply only to certain cases of this puzzling disorder.
Our explanation of the hyperlactacidemia in some cases of liver glycogen disease, and its amelioration by glucose, postulates spontaneous hepatic glycogenolysis in response to fasting hypoglycemia and shift toward glycogen deposition when the blood glucose level is raised-i.e., metabolic turnover of liver glycogen. This view was presented earlier by Mason and Sly. This is contradictory to the concept of storage of metabolically unavailable liver glycogen expressed by some authors and implied in the term "glycogen storage disease," used by many. On critical examination, however, the evidence against active metabolic turnover of glycogen in this disease proves to be largely inferential. Many observers have assumed that failure of the blood glucose to rise after administration of glucagon or epinephrine indicates that glycogenolysis did not occur. Such an assumption may be quite erroneous even when the pathways of glycogen breakdown are normal (29) and would certainly be erroneous if the end-product of glycogenolysis is lactate. The fact that glycogenolysis could occur in this disease, either through the glycolytic pathway or through the phosphogluconate pathway, was emphasized by Cori and Cori (30) .
In the six patients forming the subject of this report, lactate replaced glucose as the major in vivo end-product of hepatic glycogenolysis. Assuming that as in the normal, glucose-6-phosphate is the intermediate from which the metabolic pathways diverge, the sequence of events in these cases might be represented as in Figure 5 . It is concluded that active breakdown of liver glycogen occurred in these patients in response to the stimulus of hypoglycemia, and that glucagon exerted its usual hepatic glycogenolytic effect. However, the principal end-product of liver glycogen breakdown, whether spontaneous or glucagoninduced, was lactic acid rather than glucose.
